Alliance Wealth Management Group boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,916 shares of the company’s stock after purchasing an additional 140 shares during the quarter. Alliance Wealth Management Group’s holdings in Johnson & Johnson were worth $917,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently added to or reduced their stakes in the company. Sierra Capital LLC increased its holdings in Johnson & Johnson by 0.6% in the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after buying an additional 61 shares during the period. MTM Investment Management LLC increased its stake in Johnson & Johnson by 0.5% in the first quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock valued at $1,749,000 after acquiring an additional 61 shares during the period. Lockerman Financial Group Inc. raised its position in Johnson & Johnson by 2.4% in the fourth quarter. Lockerman Financial Group Inc. now owns 2,684 shares of the company’s stock worth $474,000 after purchasing an additional 62 shares in the last quarter. OneAscent Financial Services LLC boosted its stake in Johnson & Johnson by 3.3% in the first quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock valued at $308,000 after acquiring an additional 63 shares during the last quarter. Finally, Addison Advisors LLC raised its holdings in shares of Johnson & Johnson by 0.8% during the fourth quarter. Addison Advisors LLC now owns 7,862 shares of the company’s stock worth $1,389,000 after acquiring an additional 64 shares during the period. 67.57% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts have recently issued reports on JNJ shares. JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Raymond James lifted their target price on Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a research report on Monday, July 24th. Morgan Stanley reiterated an “equal weight” rating and set a $187.00 price objective on shares of Johnson & Johnson in a research note on Friday, July 21st. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, July 31st. Eight analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $171.80.
Insider Buying and Selling
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,163 shares of company stock worth $7,928,856. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Price Performance
NYSE:JNJ opened at $173.85 on Monday. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The firm’s 50-day simple moving average is $164.90 and its 200 day simple moving average is $161.14. The firm has a market cap of $451.83 billion, a price-to-earnings ratio of 35.19, a P/E/G ratio of 2.92 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the firm earned $2.59 earnings per share. As a group, sell-side analysts predict that Johnson & Johnson will post 10.75 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.74%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 96.36%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 8/7 – 8/11
- What is a Low P/E Ratio and What Does it Tell Investors?
- 3 Retailers To Watch Closely Next Week
- Investing in Blue-Chip Stocks
- Investing in Coffee: 3 Great Strategies to Consider
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
